Which has higher valuation & earnings, FBRX or BNTC?

Forte Biosciences is trading at a lower price-to-earnings ratio than Benitec Biopharma, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Forte Biosciences N/A N/A -$69.38M -$4.65 N/A Benitec Biopharma N/A N/A -$37.92M -$0.98 N/A

Is FBRX or BNTC more profitable?

Benitec Biopharma's return on equity of -28.41% beat Forte Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Forte Biosciences N/A -94.82% -77.68% Benitec Biopharma N/A -28.41% -27.76%

Is TSHA or BNTC more profitable?

Benitec Biopharma's return on equity of -28.41% beat Taysha Gene Therapies' return on equity. Company Net Margins Return on Equity Return on Assets Taysha Gene Therapies N/A -56.19% -41.84% Benitec Biopharma N/A -28.41% -27.76%

Does the media prefer TSHA or BNTC?

In the previous week, Benitec Biopharma had 8 more articles in the media than Taysha Gene Therapies. MarketBeat recorded 12 mentions for Benitec Biopharma and 4 mentions for Taysha Gene Therapies. Taysha Gene Therapies' average media sentiment score of 0.94 beat Benitec Biopharma's score of 0.42 indicating that Taysha Gene Therapies is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Taysha Gene Therapies 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Benitec Biopharma 0 Very Positive mention(s) 3 Positive mention(s) 4 Neutral mention(s) 3 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer BNTC or SNDX?

In the previous week, Benitec Biopharma had 8 more articles in the media than Syndax Pharmaceuticals. MarketBeat recorded 12 mentions for Benitec Biopharma and 4 mentions for Syndax Pharmaceuticals. Syndax Pharmaceuticals' average media sentiment score of 0.88 beat Benitec Biopharma's score of 0.42 indicating that Syndax Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Benitec Biopharma 0 Very Positive mention(s) 3 Positive mention(s) 4 Neutral mention(s) 3 Negative mention(s) 0 Very Negative mention(s) Neutral Syndax Pharmaceuticals 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is INBX or BNTC more profitable?

Benitec Biopharma's return on equity of -28.41% beat Inhibrx Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Inhibrx Biosciences N/A -563.90% -83.48% Benitec Biopharma N/A -28.41% -27.76%

Does the media favor INBX or BNTC?

In the previous week, Benitec Biopharma had 3 more articles in the media than Inhibrx Biosciences. MarketBeat recorded 12 mentions for Benitec Biopharma and 9 mentions for Inhibrx Biosciences. Inhibrx Biosciences' average media sentiment score of 1.05 beat Benitec Biopharma's score of 0.42 indicating that Inhibrx Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Inhibrx Biosciences 5 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Benitec Biopharma 0 Very Positive mention(s) 3 Positive mention(s) 4 Neutral mention(s) 3 Negative mention(s) 0 Very Negative mention(s) Neutral

Benitec Biopharma (BNTC) Competitors

$11.02 -0.34 (-2.99%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$11.00 -0.03 (-0.23%)

As of 09/18/2026 04:14 PM Eastern

Compare

BNTC vs. FBRX, TSHA, SNDX, INBX, and ANAB

Should you buy Benitec Biopharma stock or one of its competitors? Benitec Biopharma's main competitors and comparable companies include Forte Biosciences (FBRX), Taysha Gene Therapies (TSHA), Syndax Pharmaceuticals (SNDX), Inhibrx Biosciences (INBX), and AnaptysBio (ANAB). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Benitec Biopharma compare to Forte Biosciences?

Forte Biosciences (NASDAQ:FBRX) and Benitec Biopharma (NASDAQ:BNTC) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their analyst recommendations, profitability, media sentiment, institutional ownership, risk, valuation, earnings and dividends.

Forte Biosciences is trading at a lower price-to-earnings ratio than Benitec Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Forte Biosciences	N/A	N/A	-$69.38M	-$4.65	N/A
Benitec Biopharma	N/A	N/A	-$37.92M	-$0.98	N/A

77.6% of Forte Biosciences shares are held by institutional investors. Comparatively, 52.2% of Benitec Biopharma shares are held by institutional investors. 4.4% of Forte Biosciences shares are held by insiders. Comparatively, 4.8% of Benitec Biopharma shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Benitec Biopharma's return on equity of -28.41% beat Forte Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Forte Biosciences	N/A	-94.82%	-77.68%
Benitec Biopharma	N/A	-28.41%	-27.76%

Forte Biosciences presently has a consensus target price of $71.67, suggesting a potential downside of 6.91%. Benitec Biopharma has a consensus target price of $24.00, suggesting a potential upside of 117.79%. Given Benitec Biopharma's stronger consensus rating and higher probable upside, analysts clearly believe Benitec Biopharma is more favorable than Forte Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Forte Biosciences	1 Sell rating(s)	4 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Benitec Biopharma	1 Sell rating(s)	2 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.60

Forte Biosciences has a beta of 2.62, meaning that its share price is 162% more volatile than the broader market. Comparatively, Benitec Biopharma has a beta of 0.27, meaning that its share price is 73% less volatile than the broader market.

In the previous week, Benitec Biopharma had 12 more articles in the media than Forte Biosciences. MarketBeat recorded 12 mentions for Benitec Biopharma and 0 mentions for Forte Biosciences. Benitec Biopharma's average media sentiment score of 0.42 beat Forte Biosciences' score of 0.00 indicating that Benitec Biopharma is being referred to more favorably in the news media.

Company	Overall Sentiment
Forte Biosciences	Neutral
Benitec Biopharma	Neutral

Summary

Benitec Biopharma beats Forte Biosciences on 11 of the 13 factors compared between the two stocks.

How does Benitec Biopharma compare to Taysha Gene Therapies?

Taysha Gene Therapies (NASDAQ:TSHA) and Benitec Biopharma (NASDAQ:BNTC) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, media sentiment, risk, institutional ownership, profitability, analyst recommendations, valuation and dividends.

Benitec Biopharma has lower revenue, but higher earnings than Taysha Gene Therapies. Taysha Gene Therapies is trading at a lower price-to-earnings ratio than Benitec Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Taysha Gene Therapies	$9.77M	167.42	-$109M	-$0.42	N/A
Benitec Biopharma	N/A	N/A	-$37.92M	-$0.98	N/A

In the previous week, Benitec Biopharma had 8 more articles in the media than Taysha Gene Therapies. MarketBeat recorded 12 mentions for Benitec Biopharma and 4 mentions for Taysha Gene Therapies. Taysha Gene Therapies' average media sentiment score of 0.94 beat Benitec Biopharma's score of 0.42 indicating that Taysha Gene Therapies is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Taysha Gene Therapies	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Benitec Biopharma	0 Very Positive mention(s)	3 Positive mention(s)	4 Neutral mention(s)	3 Negative mention(s)	0 Very Negative mention(s)	Neutral

77.7% of Taysha Gene Therapies shares are owned by institutional investors. Comparatively, 52.2% of Benitec Biopharma shares are owned by institutional investors. 3.5% of Taysha Gene Therapies shares are owned by insiders. Comparatively, 4.8% of Benitec Biopharma shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Taysha Gene Therapies currently has a consensus price target of $12.77, suggesting a potential upside of 154.37%. Benitec Biopharma has a consensus price target of $24.00, suggesting a potential upside of 117.79%. Given Taysha Gene Therapies' stronger consensus rating and higher probable upside, analysts plainly believe Taysha Gene Therapies is more favorable than Benitec Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Taysha Gene Therapies	1 Sell rating(s)	0 Hold rating(s)	12 Buy rating(s)	2 Strong Buy rating(s)	3.00
Benitec Biopharma	1 Sell rating(s)	2 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.60

Benitec Biopharma's return on equity of -28.41% beat Taysha Gene Therapies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Taysha Gene Therapies	N/A	-56.19%	-41.84%
Benitec Biopharma	N/A	-28.41%	-27.76%

Taysha Gene Therapies has a beta of 1.19, suggesting that its stock price is 19% more volatile than the broader market. Comparatively, Benitec Biopharma has a beta of 0.27, suggesting that its stock price is 73% less volatile than the broader market.

Summary

Taysha Gene Therapies beats Benitec Biopharma on 9 of the 15 factors compared between the two stocks.

How does Benitec Biopharma compare to Syndax Pharmaceuticals?

Benitec Biopharma (NASDAQ:BNTC) and Syndax Pharmaceuticals (NASDAQ:SNDX) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their dividends, media sentiment, risk, institutional ownership, earnings, analyst recommendations, profitability and valuation.

In the previous week, Benitec Biopharma had 8 more articles in the media than Syndax Pharmaceuticals. MarketBeat recorded 12 mentions for Benitec Biopharma and 4 mentions for Syndax Pharmaceuticals. Syndax Pharmaceuticals' average media sentiment score of 0.88 beat Benitec Biopharma's score of 0.42 indicating that Syndax Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Benitec Biopharma	0 Very Positive mention(s)	3 Positive mention(s)	4 Neutral mention(s)	3 Negative mention(s)	0 Very Negative mention(s)	Neutral
Syndax Pharmaceuticals	3 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Benitec Biopharma has higher earnings, but lower revenue than Syndax Pharmaceuticals. Benitec Biopharma is trading at a lower price-to-earnings ratio than Syndax Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Benitec Biopharma	N/A	N/A	-$37.92M	-$0.98	N/A
Syndax Pharmaceuticals	$172.35M	9.06	-$285.42M	-$2.51	N/A

Benitec Biopharma currently has a consensus price target of $24.00, indicating a potential upside of 117.79%. Syndax Pharmaceuticals has a consensus price target of $42.30, indicating a potential upside of 140.07%. Given Syndax Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Syndax Pharmaceuticals is more favorable than Benitec Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Benitec Biopharma	1 Sell rating(s)	2 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.60
Syndax Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.82

52.2% of Benitec Biopharma shares are owned by institutional investors. 4.8% of Benitec Biopharma shares are owned by insiders. Comparatively, 4.8% of Syndax Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Benitec Biopharma has a net margin of 0.00% compared to Syndax Pharmaceuticals' net margin of -87.52%. Benitec Biopharma's return on equity of -28.41% beat Syndax Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Benitec Biopharma	N/A	-28.41%	-27.76%
Syndax Pharmaceuticals	-87.52%	-372.94%	-39.11%

Benitec Biopharma has a beta of 0.27, indicating that its stock price is 73% less volatile than the broader market. Comparatively, Syndax Pharmaceuticals has a beta of 0.37, indicating that its stock price is 63% less volatile than the broader market.

Summary

Benitec Biopharma and Syndax Pharmaceuticals tied by winning 7 of the 14 factors compared between the two stocks.

How does Benitec Biopharma compare to Inhibrx Biosciences?

Inhibrx Biosciences (NASDAQ:INBX) and Benitec Biopharma (NASDAQ:BNTC) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, valuation, profitability, analyst recommendations, dividends, media sentiment, institutional ownership and risk.

Inhibrx Biosciences currently has a consensus target price of $197.50, suggesting a potential upside of 80.61%. Benitec Biopharma has a consensus target price of $24.00, suggesting a potential upside of 117.79%. Given Benitec Biopharma's stronger consensus rating and higher probable upside, analysts clearly believe Benitec Biopharma is more favorable than Inhibrx Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Inhibrx Biosciences	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.50
Benitec Biopharma	1 Sell rating(s)	2 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.60

Benitec Biopharma's return on equity of -28.41% beat Inhibrx Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Inhibrx Biosciences	N/A	-563.90%	-83.48%
Benitec Biopharma	N/A	-28.41%	-27.76%

82.5% of Inhibrx Biosciences shares are owned by institutional investors. Comparatively, 52.2% of Benitec Biopharma shares are owned by institutional investors. 18.3% of Inhibrx Biosciences shares are owned by insiders. Comparatively, 4.8% of Benitec Biopharma shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Benitec Biopharma has lower revenue, but higher earnings than Inhibrx Biosciences. Inhibrx Biosciences is trading at a lower price-to-earnings ratio than Benitec Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Inhibrx Biosciences	$1.30M	1,238.18	-$140.05M	-$8.88	N/A
Benitec Biopharma	N/A	N/A	-$37.92M	-$0.98	N/A

Inhibrx Biosciences has a beta of 3.66, suggesting that its stock price is 266% more volatile than the broader market. Comparatively, Benitec Biopharma has a beta of 0.27, suggesting that its stock price is 73% less volatile than the broader market.

In the previous week, Benitec Biopharma had 3 more articles in the media than Inhibrx Biosciences. MarketBeat recorded 12 mentions for Benitec Biopharma and 9 mentions for Inhibrx Biosciences. Inhibrx Biosciences' average media sentiment score of 1.05 beat Benitec Biopharma's score of 0.42 indicating that Inhibrx Biosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Inhibrx Biosciences	5 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Benitec Biopharma	0 Very Positive mention(s)	3 Positive mention(s)	4 Neutral mention(s)	3 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Benitec Biopharma beats Inhibrx Biosciences on 9 of the 15 factors compared between the two stocks.

How does Benitec Biopharma compare to AnaptysBio?

Benitec Biopharma (NASDAQ:BNTC) and AnaptysBio (NASDAQ:ANAB) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their analyst recommendations, valuation, dividends, media sentiment, institutional ownership, profitability, earnings and risk.

Benitec Biopharma has a net margin of 0.00% compared to AnaptysBio's net margin of -11.53%. AnaptysBio's return on equity of 0.00% beat Benitec Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Benitec Biopharma	N/A	-28.41%	-27.76%
AnaptysBio	-11.53%	N/A	-7.75%

Benitec Biopharma has a beta of 0.27, meaning that its share price is 73% less volatile than the broader market. Comparatively, AnaptysBio has a beta of 0.71, meaning that its share price is 29% less volatile than the broader market.

52.2% of Benitec Biopharma shares are owned by institutional investors. 4.8% of Benitec Biopharma shares are owned by company insiders. Comparatively, 31.5% of AnaptysBio shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

AnaptysBio has higher revenue and earnings than Benitec Biopharma. AnaptysBio is trading at a lower price-to-earnings ratio than Benitec Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Benitec Biopharma	N/A	N/A	-$37.92M	-$0.98	N/A
AnaptysBio	$234.60M	6.97	-$13.23M	-$1.08	N/A

Benitec Biopharma presently has a consensus price target of $24.00, suggesting a potential upside of 117.79%. AnaptysBio has a consensus price target of $79.85, suggesting a potential upside of 44.65%. Given Benitec Biopharma's higher possible upside, equities research analysts clearly believe Benitec Biopharma is more favorable than AnaptysBio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Benitec Biopharma	1 Sell rating(s)	2 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.60
AnaptysBio	1 Sell rating(s)	3 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.67

In the previous week, Benitec Biopharma had 12 more articles in the media than AnaptysBio. MarketBeat recorded 12 mentions for Benitec Biopharma and 0 mentions for AnaptysBio. Benitec Biopharma's average media sentiment score of 0.42 beat AnaptysBio's score of 0.00 indicating that Benitec Biopharma is being referred to more favorably in the media.

Company	Overall Sentiment
Benitec Biopharma	Neutral
AnaptysBio	Neutral

Summary

AnaptysBio beats Benitec Biopharma on 8 of the 15 factors compared between the two stocks.

Get Benitec Biopharma News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BNTC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

BNTC vs. The Competition

Export

Metric	Benitec Biopharma	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$396.27M	$3.92B	$7.24B	$13.14B
Dividend Yield	N/A	3.65%	2.57%	12.30%
P/E Ratio	-11.24	14.30	275.79	25.40
Price / Sales	N/A	1,415.50	695.58	114.44
Price / Cash	N/A	110.75	77.42	51.66
Price / Book	2.97	15.45	10.46	6.33
Net Income	-$37.92M	-$22.86M	$3.49B	$358.33M
7 Day Performance	-9.60%	-1.21%	0.59%	1.12%
1 Month Performance	-17.64%	-4.42%	-2.01%	-2.67%
1 Year Performance	-18.07%	37.81%	18.09%	6.01%

Benitec Biopharma Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
BNTC Benitec Biopharma	1.8177 of 5 stars	$11.02 -3.0%	$24.00 +117.8%	-21.2%	$384.41M	N/A	N/A	19	News Coverage Earnings Report Analyst Forecast High Trading Volume
FBRX Forte Biosciences	0.9629 of 5 stars	$76.99 flat	$71.67 -6.9%	N/A	$1.63B	N/A	N/A	5
TSHA Taysha Gene Therapies	3.1768 of 5 stars	$5.06 +1.0%	$12.77 +152.4%	+67.9%	$1.63B	$9.77M	N/A	99	News Coverage Positive News Analyst Forecast High Trading Volume
SNDX Syndax Pharmaceuticals	3.4575 of 5 stars	$18.09 -1.4%	$42.30 +133.8%	+14.0%	$1.63B	$172.35M	N/A	298	Analyst Downgrade
INBX Inhibrx Biosciences	3.7673 of 5 stars	$105.61 -4.4%	$197.50 +87.0%	+310.3%	$1.63B	$1.30M	N/A	110	Positive News Analyst Forecast Insider Trade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:BNTC) was last updated on 9/19/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Benitec Biopharma (BNTC) Competitors

BNTC vs. FBRX, TSHA, SNDX, INBX, and ANAB

How does Benitec Biopharma compare to Forte Biosciences?

Summary

How does Benitec Biopharma compare to Taysha Gene Therapies?

Summary

How does Benitec Biopharma compare to Syndax Pharmaceuticals?

Summary

How does Benitec Biopharma compare to Inhibrx Biosciences?

Summary

How does Benitec Biopharma compare to AnaptysBio?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BNTC vs. The Competition

Benitec Biopharma Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Benitec Biopharma (BNTC) Competitors

BNTC vs. FBRX, TSHA, SNDX, INBX, and ANAB

How does Benitec Biopharma compare to Forte Biosciences?

Which has higher valuation & earnings, FBRX or BNTC?

Do institutionals & insiders have more ownership in FBRX or BNTC?

Is FBRX or BNTC more profitable?

Do analysts rate FBRX or BNTC?

Which has more volatility & risk, FBRX or BNTC?

Does the media prefer FBRX or BNTC?

Summary

How does Benitec Biopharma compare to Taysha Gene Therapies?

Which has stronger earnings & valuation, TSHA or BNTC?

Does the media prefer TSHA or BNTC?

Do institutionals & insiders have more ownership in TSHA or BNTC?

Do analysts recommend TSHA or BNTC?

Is TSHA or BNTC more profitable?

Which has more volatility and risk, TSHA or BNTC?

Summary

How does Benitec Biopharma compare to Syndax Pharmaceuticals?

Does the media prefer BNTC or SNDX?

Which has stronger valuation and earnings, BNTC or SNDX?

Do analysts rate BNTC or SNDX?

Do institutionals & insiders believe in BNTC or SNDX?

Is BNTC or SNDX more profitable?

Which has more risk & volatility, BNTC or SNDX?

Summary

How does Benitec Biopharma compare to Inhibrx Biosciences?

Do analysts prefer INBX or BNTC?

Is INBX or BNTC more profitable?

Do insiders & institutionals hold more shares of INBX or BNTC?

Which has better valuation and earnings, INBX or BNTC?

Which has more volatility and risk, INBX or BNTC?

Does the media favor INBX or BNTC?

Summary

How does Benitec Biopharma compare to AnaptysBio?

Is BNTC or ANAB more profitable?

Which has more volatility and risk, BNTC or ANAB?

Do insiders and institutionals hold more shares of BNTC or ANAB?

Which has better valuation & earnings, BNTC or ANAB?

Do analysts recommend BNTC or ANAB?

Does the media favor BNTC or ANAB?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BNTC vs. The Competition

Benitec Biopharma Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools